Vitamin D deficiency and COVID-19: A case-control study at a tertiary care hospital in India
Nimavat et al.,
Vitamin D deficiency and COVID-19: A case-control study at a tertiary care hospital in India,
Annals of Medicine and Surgery, doi:10.1016/j.amsu.2021.102661
Case control study with 156 PCR+ cases in India and 204 controls, showing more frequent vitamin D deficiency in COVID-19 patients, and an association between lower vitamin D levels and COVID-19 severity.
risk of death, 50.4% lower, RR 0.50, p = 0.17, high D levels 13 of 131 (9.9%), low D levels 5 of 25 (20.0%), NNT 9.9, >10ng/mL, within cases.
|
risk of severe case, 67.6% lower, RR 0.32, p = 0.003, high D levels 17 of 131 (13.0%), low D levels 10 of 25 (40.0%), NNT 3.7, >10ng/mL, within cases.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Nimavat et al., 5 Aug 2021, retrospective, India, peer-reviewed, 5 authors.
Abstract: Annals of Medicine and Surgery 68 (2021) 102661
Contents lists available at ScienceDirect
Annals of Medicine and Surgery
journal homepage: www.elsevier.com/locate/amsu
Case-controlled Study
Vitamin D deficiency and COVID-19: A case-control study at a tertiary care
hospital in India
Nirav Nimavat a, Shruti Singh b, *, Pratibha Singh c, Sunil Kumar Singh b, Nishi Sinha b
a
Department of Community Medicine, SBKS MIRC, Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India
Department of Pharmacology, AIIMS, Patna, Bihar, India
c
Department of Anaesthesiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
b
A R T I C L E I N F O
A B S T R A C T
Keywords:
Vitamin D
COVID-19
Case-control
Clinical severity
Background: As the pandemic COVID-19 affected developing and developed countries, there is no proven
treatment options available yet. The anti-inflammatory, antiviral and immune modulator effect of Vitamin D
could be beneficial to COVID-19.
Aim: To find out the possible association between Vitamin D and COVID-19.
Methods: The present case-control study was conducted at tertiary care hospital, AIIMS, Patna, Bihar, India. Total
156 cases and 204 controls were enrolled in the study after obtaining informed consent. Categorization of the
patients were done based on clinical severity and level of Vitamin D. The association between these categories
with different variables were analyzed using regression analysis and other statistical tests.
Results: The status of Vitamin D (optimal, mild to moderate deficiency and severe deficiency) differed signifi
cantly among cases and controls. Diabetes and hypertension were most prevalent comorbidities among cases. On
regression analysis, the difference in Vitamin D level was significant (aOR, 3.295; 95%CI, 1.25–8.685). The
association between Vitamin D status and clinical severity group was statistically significant among cases. Among
all variables, age, diabetes, hypertension and clinical severity were associated with worst outcome.
Conclusion: Vitamin D status appears to be strongly associated with COVID-19 clinical severity. After COVID-19
confirmation, Vitamin D level should be measured in all patients and curative plus preventive therapy should be
initiated.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit